Printer Friendly

SYNTRO FORMS JOINT VENTURE TO COMMERCIALIZE POULTRY VACCINES

 KANSAS CITY, Kan., Feb. 24 /PRNewswire/ -- Syntro Corp. (NASDAQ: SYNT) announced today the formation of Syntro Zeon L.C., a 50-50 joint venture between Syntro Venture Corp. (a wholly owned subsidiary of Syntro Corp.) and Nippon Zeon of America Inc. (a wholly owned subsidiary of Nippon Zeon Co. Ltd. of Tokyo). The joint venture was established as a Kansas-limited liability company, with headquarters in Lenexa, Kan., a suburb of Kansas City.
 Syntro Zeon will commercialize a family of poultry vaccines expected to emerge from a collaborative product development program initiated by Syntro and Nippon Zeon in 1989. The vaccines currently under development are genetically designed to deliver enhanced performance against four of the most prevalent and economically important diseases affecting the poultry industry worldwide. They incorporate viral gene engineering technologies developed by Syntro and Nippon Zeon scientists.
 Initial vaccines from the product development collaboration are in the more advanced stages of the USDA approval process. Manufacturing of products for the U.S. market will be carried out by SyntroVet Inc., Syntro's wholly owned animal health company.
 Sales of poultry vaccines comprise approximately 20 percent of the estimated $1.5 billion, worldwide veterinary vaccine market. Poultry flocks are routinely vaccinated to minimize the impact of infectious diseases on meat and egg production. As a key element of its strategy, Syntro is addressing opportunities in the poultry sector through Syntro Zeon as well as through a separate collaboration with Hoechst-Roussel Agri-Vet Co.
 Nippon Zeon is a leading chemical company engaged in the development, manufacturing and sales of synthetic rubber, plastics, specialty chemicals and medical products. During the past decade, Nippon Zeon has been active in developing and acquiring new technologies in the area of life sciences.
 Syntro Corp. is a Kansas City and San Diego-based biotechnology company engaged in the development and commercialization of genetically engineered vaccines for the animal health sector.
 -0- 2/24/93
 /CONTACT: J. Donald Todd, president and CEO, or William J. Davies, VP of Syntro Corp., 913-888-8876/
 (SYNT)


CO: Syntro Corp.; Nippon Zeon of America Inc.; Syntro Zeon L.C. ST: Kansas IN: MTC CHM SU: JVN

MS-BP -- DV006 -- 9965 02/24/93 14:04 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 24, 1993
Words:359
Previous Article:FORD DIVISION REPORTS 10-DAY SALES
Next Article:SPORTS/LEISURE, INC. ANNOUNCES SALE OF SUBSIDIARY TO THE BEN HOGAN COMPANY
Topics:


Related Articles
SYNTRO REPORTS FIRST QUARTER PROFIT
SYNTRO FILES REGISTRATION STATEMENT FOR PUBLIC OFFERING OF 3,000,000 SHARES
SUSAN STROBEL TO JOIN SYNTRO AS VICE PRESIDENT OF FINANCE AND CFO
SYNTRO CORPORATION REPORTS THIRD QUARTER RESULTS
SYNTRO REPORTS FIRST QUARTER RESULTS; ANNUAL MEETING HIGHLIGHTS TECHNOLOGY MILESTONES
SMITHKLINE BEECHAM AND MICROCARB FORM ALLIANCE TO DEVELOP HUMAN VACCINES
Antex Biologics Reports Third Quarter Financial Results
Embrex's In Ovo Vaccine, Bursaplex(TM), Receives Regulatory Approval From Thailand
VaxGen to Hold Conference Call on March 28 to Provide Update on Celltrion Joint Venture.
VaxGen finalizes commercial rights to anthrax vaccine.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters